A prospective open-label trial; Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after endothelial keratoplasty (DSAEK or DMEK)

A prospective open-label trial; Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after endothelial keratoplasty (DSAEK or DMEK) - Prevention of cystoid macla oedema after endothelial keratoplasty using bromfenac

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027924

Enrollment

Registered

2017-07-01

Start date

2017-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bullous keratopathy

Interventions

EK with topical 0.1% bromfenac sodium ophthalmic solution EK without topical 0.1% bromfenac sodium ophthalmic solution

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with bullous keratoplathy, who agree with this study

Exclusion criteria

Exclusion criteria: patients without bullous keratoplathy, who agree with this study

Design outcomes

Primary

Measure	Time frame
central foveal thickness preoperatively, and 1, 3, 6, 12 months postoperatively after endothelial keratoplasty	—

Secondary

Measure	Time frame
the best-corrected visual acuity (BCVA), central corneal thickness(CCT), and corneal endothelial cell density(ECD), preoperatively, and 1, 3, 6, 12 months postoperatively after endothelial keratoplasty	—

Countries

Japan

Contacts

Public ContactTakahiko Hayashi

Yokohama Minami Kyosai Hospital Ophthalmology

takamed@gmail.com0457822101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026